Literature DB >> 8415717

Significant enlargement of a specific subset of CD3+CD8+ peripheral blood leukocytes mediating cytotoxic T-lymphocyte activity during human immunodeficiency virus infection.

A Bensussan1, C Rabian, V Schiavon, D Bengoufa, G Leca, L Boumsell.   

Abstract

We have obtained a monoclonal antibody termed BY55 that defines an 80-kDa cell-surface structure on a subset of circulating peripheral blood mononucleocytes. This structure, which was not detected on most cell lines or activated lymphocytes, was expressed exclusively on 15-25% of CD2+ circulating lymphocytes, including a major subset within the CD3- and the T-cell receptor gamma delta + lymphocytes and a small percentage of the CD3+CD8+ cells. Moreover, we have shown that the BY55 molecule delineated the competent killer circulating lymphocytes. In the present report, additional two- and three-color immunofluorescence studies of peripheral blood lymphocytes were done to precisely determine BY55 expression within the T-cell population. In normal individuals, peripheral blood CD3+CD8+BY55+ cells represented only 5-6% of the lymphocytes, and these cells possessed cytolytic activity. Interestingly, we found that the percentage of total BY55+ lymphocytes as well as the percentage of CD3+CD8+BY55+ was significantly increased in peripheral blood lymphocytes of human immunodeficiency virus-seropositive individuals.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8415717      PMCID: PMC47581          DOI: 10.1073/pnas.90.20.9427

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  Interaction between CD4 and class II MHC molecules mediates cell adhesion.

Authors:  C Doyle; J L Strominger
Journal:  Nature       Date:  1987 Nov 19-25       Impact factor: 49.962

2.  Prognostic significance of cytotoxic T cells in individuals infected with human immunodeficiency virus.

Authors:  C Mihailov; A Lamour; V Beaudré-Bellein; N Jézequel; M Garré; D Mottier; G Guillet; P Youinou
Journal:  J Clin Immunol       Date:  1993-03       Impact factor: 8.317

3.  Disproportionate expansion of a minor T cell subset in patients with lymphadenopathy syndrome and acquired immunodeficiency syndrome.

Authors:  D E Lewis; J M Puck; G F Babcock; R R Rich
Journal:  J Infect Dis       Date:  1985-03       Impact factor: 5.226

4.  Identification of a putative second T-cell receptor.

Authors:  M B Brenner; J McLean; D P Dialynas; J L Strominger; J A Smith; F L Owen; J G Seidman; S Ip; F Rosen; M S Krangel
Journal:  Nature       Date:  1986 Jul 10-16       Impact factor: 49.962

Review 5.  The interleukin 2 receptor.

Authors:  K A Smith
Journal:  Adv Immunol       Date:  1988       Impact factor: 3.543

6.  Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro.

Authors:  I S Trowbridge; F Lopez
Journal:  Proc Natl Acad Sci U S A       Date:  1982-02       Impact factor: 11.205

7.  CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication.

Authors:  C M Walker; D J Moody; D P Stites; J A Levy
Journal:  Science       Date:  1986-12-19       Impact factor: 47.728

8.  Interleukin 2 high-affinity receptor expression requires two distinct binding proteins.

Authors:  K Teshigawara; H M Wang; K Kato; K A Smith
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

9.  Clonotypic structures involved in antigen-specific human T cell function. Relationship to the T3 molecular complex.

Authors:  S C Meuer; K A Fitzgerald; R E Hussey; J C Hodgdon; S F Schlossman; E L Reinherz
Journal:  J Exp Med       Date:  1983-02-01       Impact factor: 14.307

10.  A novel 80-kD cell surface structure identifies human circulating lymphocytes with natural killer activity.

Authors:  H Maïza; G Leca; I G Mansur; V Schiavon; L Boumsell; A Bensussan
Journal:  J Exp Med       Date:  1993-09-01       Impact factor: 14.307

View more
  10 in total

1.  Differential and tumor-specific expression of CD160 in B-cell malignancies.

Authors:  Timothy W Farren; Jerome Giustiniani; Feng-Ting Liu; Dimitris A Tsitsikas; Marion G Macey; James D Cavenagh; Heather E Oakervee; David Taussig; Adrian C Newland; Maria Calaminici; Armand Bensussan; Michael Jenner; John G Gribben; Samir G Agrawal
Journal:  Blood       Date:  2011-06-28       Impact factor: 22.113

2.  BY55 monoclonal antibody delineates within human cord blood and bone marrow lymphocytes distinct cell subsets mediating cytotoxic activity.

Authors:  A Bensussan; E Gluckman; S el Marsafy; V Schiavon; I G Mansur; J Dausset; L Boumsell; E Carosella
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

3.  CD160 signaling mediates PI3K-dependent survival and growth signals in chronic lymphocytic leukemia.

Authors:  Feng-Ting Liu; Jerome Giustiniani; Timothy Farren; Li Jia; Armand Bensussan; John G Gribben; Samir G Agrawal
Journal:  Blood       Date:  2010-02-17       Impact factor: 22.113

4.  BY55/CD160 cannot be considered a cytotoxic marker in cytomegalovirus-specific human CD8(+) T cells.

Authors:  J Merino; N Ramírez; C Moreno; E Toledo; M Fernández; A Sánchez-Ibarrola
Journal:  Clin Exp Immunol       Date:  2007-04-11       Impact factor: 4.330

5.  Minimal residual disease detection with tumor-specific CD160 correlates with event-free survival in chronic lymphocytic leukemia.

Authors:  T W Farren; J Giustiniani; M Fanous; F Liu; M G Macey; F Wright; A Prentice; A Nathwani; S G Agrawal
Journal:  Blood Cancer J       Date:  2015-01-23       Impact factor: 11.037

Review 6.  Immunometabolic Regulations Mediated by Coinhibitory Receptors and Their Impact on T Cell Immune Responses.

Authors:  Nikolaos Patsoukis; Jessica D Weaver; Laura Strauss; Christoph Herbel; Pankaj Seth; Vassiliki A Boussiotis
Journal:  Front Immunol       Date:  2017-04-11       Impact factor: 7.561

7.  Gamma/Delta T Cells in the Course of Healthy Human Pregnancy: Cytotoxic Potential and the Tendency of CD8 Expression Make CD56+ γδT Cells a Unique Lymphocyte Subset.

Authors:  Jasper Nörenberg; Pál Jaksó; Alíz Barakonyi
Journal:  Front Immunol       Date:  2021-02-02       Impact factor: 7.561

8.  Highly Sensitive and Accurate Assessment of Minimal Residual Disease in Chronic Lymphocytic Leukemia Using the Novel CD160-ROR1 Assay.

Authors:  Timothy W Farren; Kaushik S Sadanand; Samir G Agrawal
Journal:  Front Oncol       Date:  2020-12-03       Impact factor: 6.244

9.  Evaluation of CD160 and CD200 Expression as Differentiating Markers between Chronic Lymphocytic Leukemia and Other Mature B-Cell Neoplasms.

Authors:  Wafaa Ahmed El-Neanaey; Rania Shafik Swelem; Omar Mohamed Ghallab; Sara Mohamed Abu-Shelou
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2020-01-01

Review 10.  Measurable residual disease in the treatment of chronic lymphocytic leukemia.

Authors:  Takayoshi Uchiyama; Aki Yokoyama; Sadao Aoki
Journal:  J Clin Exp Hematop       Date:  2020-11-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.